Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells $2,554,826.10 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 57,606 shares of the company’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the sale, the senior vice president now directly owns 4,841 shares of the company’s stock, valued at $214,698.35. The trade was a 92.25 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 3rd, Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $51,306.08.
• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00.

Mirum Pharmaceuticals Stock Down 1.9 %

MIRM traded down $0.84 during trading hours on Tuesday, hitting $44.31. 350,774 shares of the company’s stock were exchanged, compared to its average volume of 513,013. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -21.94 and a beta of 1.04. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock’s 50-day moving average is $47.55 and its two-hundred day moving average is $43.60. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Robert W. Baird upped their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a report on Thursday, February 27th. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $58.20.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its stake in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after acquiring an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter valued at about $35,000. GF Fund Management CO. LTD. acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $42,000. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $69,000. Finally, AlphaQuest LLC grew its stake in Mirum Pharmaceuticals by 969.6% in the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock valued at $76,000 after buying an additional 1,658 shares during the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.